Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1b Study With Volociximab in Combination With Carboplatin and Paclitaxel in First-line, Advanced Non-Small Cell Lung Cancer (NSCLC)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~1. Males and females at least 18 years of age.~2. Stage IIIB or IV or recurrent NSCLC.~3. Measurable and/or evaluable disease according to RECIST.~4. No prior chemotherapy, biological therapy or immunotherapy for Stage IIIB/IV disease. Adjuvant therapy for early stage disease must have been completed \> or = 6 months prior to Cycle 1, Day 1 of this study.~5. Eastern Cooperative Oncology Group (ECOG) performance status \< or =1.~6. A negative pregnancy test (serum or urine) in women of childbearing potential at screening.~Exclusion Criteria~1. Known allergy or sensitivity to murine proteins, chimeric antibodies or other components of the product, Cremophor EL (polyoxyethylated castor oil), cisplatin, or other platinum-containing compounds.~2. Absolute neutrophil count (ANC) \<1500/mm3, hemoglobin level \<9 g/dL, or a platelet count \<100,000/mm3.~3. Aspartate transaminase (AST), alanine transaminase (ALT), or alkaline phosphatase values of .2.5 of the upper limits of normal values (ULN) (\>5 ULN for subjects with liver metastases) or alkaline phosphatase values \>2.5 ULN (unless documented bone metastases are responsible for the increase of alkaline phosphatase); total bilirubin \>1.5 mg/dL, or serum creatinine \>1.8 mg/dL.~4. Radiation therapy within 1 month before Cycle 1, Day 1.~5. Documented symptomatic central nervous system (CNS) tumor or CNS metastases.~6. History of thromboembolic events, including cardiovascular or cerebrovascular events (ie, acute myocardial infarction \[AMI\], stroke) within 1 year prior to Cycle 1, Day 1.~7. History of known bleeding disorders and coagulation defects.~8. History of significant hemoptysis (ie, \> or =1/2 teaspoon red blood per event) or gastrointestinal bleeding within 1 year prior to Cycle 1, Day 1.~9. Major surgery (eg, exploratory laparotomy) within 4 weeks prior to Cycle 1, Day 1 of the study.~10. Clinically significant or unstable medical conditions including, but not limited to, uncontrolled diabetes mellitus requiring insulin, uncontrolled hypertension, or uncontrolled or symptomatic orthostatic hypotension.~11. Oxygen-dependent chronic obstructive pulmonary disease.~12. Known active infections requiring intravenous (IV) antibiotics, antivirals, or antifungals, including but not limited to chronic human immunodeficiency virus, hepatitis B, or hepatitis C infection.~13. Prior bone marrow or stem cell transplant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Escalating doses of volociximab at 10, 20, and 30 (or 15) mg/kg with carboplatin and paclitaxel.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete